Europe Psychedelic Drugs Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF EUROPE PSYCHEDELIC DRUGS MARKET 26
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 SOURCE LIFELINE CURVE 37
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.9 DBMR MARKET POSITION GRID 39
2.10 MARKET APPLICATION COVERAGE GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 47
4.1 EPIDEMIOLOGY 48
4.2 PIPELINE ANALYSIS 50
5 REGULATORY FRAMEWORK: EUROPE PSYCHEDELIC DRUGS MARKET 52
5.1 REGULATORY SCENARIO IN THE U.S. 52
5.2 REGULATORY SCENARIO IN THE U.K. 53
5.3 REGULATORY SCENARIO IN INDIA 54
5.4 REGULATORY SCENARIO IN UAE 54
5.5 REGULATORY SCENARIO IN AFRICA 55
5.6 REGULATORY SCENARIO IN BRAZIL 55

6 MARKET OVERVIEW 57
6.1 DRIVERS 59
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION 59
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 61
6.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH 66
6.1.4 ONGOING CLINICAL TRIALS 67
6.1.5 RISE IN PRODUCT APPROVALS 68
6.2 RESTRAINTS 68
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 68
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 71
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 74
6.3 OPPORTUNITIES 74
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 74
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 76
6.3.3 UPCOMING REHABILITATION CENTERS 78
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 78
6.4 CHALLENGES 78
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 78
6.4.2 RISE IN ILLEGAL ALTERNATIVES 79
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 80
7 COVID-19 IMPACT ON EUROPE PSYCHEDELIC DRUGS MARKET 81
7.1 IMPACT ON PRICE 81
7.2 IMPACT ON DEMAND 81
7.3 IMPACT ON SUPPLY CHAIN 82
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 82
7.5 CONCLUSION 83
8 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE 84
8.1 OVERVIEW 85
8.2 EMPATHOGENS 88
8.3 DISSOCIATIVES 88
8.4 OTHERS 89
9 EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE 91
9.1 OVERVIEW 92
9.2 SYNTHETIC 95
9.3 NATURAL 95

10 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS 97
10.1 OVERVIEW 98
10.2 GAMMA-HYDROXYBUTYRIC ACID 101
10.3 KETAMINE 101
10.4 PSILOCYBIN 102
10.5 OTHERS 103
11 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION 105
11.1 OVERVIEW 106
11.2 NARCOLEPSY 109
11.3 TREATMENT RESISTANT DEPRESSION 109
11.4 MAJOR DEPRESSIVE DISORDER 110
11.5 OPIATE ADDICTION 111
11.6 POST-TRAUMATIC STRESS DISORDER 112
11.7 OTHERS 113
12 EUROPE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 114
12.1 OVERVIEW 115
12.2 ORAL 118
12.3 INHALATION 118
12.4 INJECTABLE 119
13 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER 121
13.1 OVERVIEW 122
13.2 HOSPITALS 125
13.3 SPECIALTY CLINICS 125
13.4 HOMECARE 126
13.5 OTHERS 127
14 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 128
14.1 OVERVIEW 129
14.2 HOSPITALS PHARMACY 132
14.3 RETAIL PHARMACY 132
14.4 ONLINE PHARMACY 133

15 EUROPE PSYCHEDELIC DRUGS MARKET, BY REGION 135
15.1 EUROPE 136
15.1.1 GERMANY 145
15.1.2 U.K. 147
15.1.3 FRANCE 149
15.1.4 ITALY 151
15.1.5 SPAIN 153
15.1.6 RUSSIA 155
15.1.7 POLAND 157
15.1.8 SWITZERLAND 159
15.1.9 NETHERLANDS 161
15.1.10 HUNGARY 163
15.1.11 AUSTRIA 165
15.1.12 NORWAY 167
15.1.13 IRELAND 169
15.1.14 BELGIUM 171
15.1.15 LITHUANIA 173
15.1.16 REST OF EUROPE 175
16 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 176
16.1 COMPANY SHARE ANALYSIS: EUROPE 176
17 SWOT ANALYSIS 177
18 COMPANY PROFILE 178
18.1 JAZZ PHARMACEUTICALS, INC. 178
18.1.1 COMPANY SNAPSHOT 178
18.1.2 REVENUE ANALYSIS 178
18.1.3 COMPANY SHARE ANALYSI 179
18.1.4 PRODUCT PORTFOLIO 179
18.1.5 RECENT DEVELOPMENTS 180
18.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 181
18.2.1 COMPANY SNAPSHOT 181
18.2.2 REVENUE ANALYSIS 181
18.2.3 COMPANY SHARE ANALYSIS 182
18.2.4 PRODUCT PORTFOLIO 182
18.2.5 RECENT DEVELOPMENTS 182

18.3 PFIZER INC. 184
18.3.1 COMPANY SNAPSHOT 184
18.3.2 REVENUE ANALYSIS 184
18.3.3 COMPANY SHARE ANALYSIS 185
18.3.4 PRODUCT PORTFOLIO 185
18.3.5 RECENT DEVELOPMENTS 185
18.4 AVADEL 187
18.4.1 COMPANY SNAPSHOT 187
18.4.2 REVENUE ANALYSIS 187
18.4.3 PRODUCT PORTFOLIO 188
18.4.4 RECENT DEVELOPMENTS 188
18.5 CELON PHARMA S.A. 189
18.5.1 COMPANY SNAPSHOT 189
18.5.2 PIPELINE PRODUCT PORTFOLIO 189
18.5.3 RECENT DEVELOPMENTS 189
18.6 COMPASS 190
18.6.1 COMPANY SNAPSHOT 190
18.6.2 PIPELINE PRODUCT PORTFOLIO 190
18.6.3 RECENT DEVELOPMENTS 190
18.7 CYBIN CORP. 191
18.7.1 COMPANY SNAPSHOT 191
18.7.2 PIPELINE PRODUCT PORTFOLIO 191
18.7.3 RECENT DEVELOPMENT 191
18.8 DEMERX 192
18.8.1 COMPANY SNAPSHOT 192
18.8.2 PIPELINE PRODUCT PORTFOLIO 192
18.8.3 RECENT DEVELOPMENT 192
18.9 EMPATHBIO 193
18.9.1 COMPANY SNAPSHOT 193
18.9.2 PIPELINE PRODUCT PORTFOLIO 193
18.9.3 RECENT DEVELOPMENT 193
18.10 F. HOFFMANN-LA ROCHE LTD 194
18.10.1 COMPANY SNAPSHOT 194
18.10.2 REVENUE ANALYSIS 194
18.10.3 PRODUCT PORTFOLIO 195
18.10.4 RECENT DEVELOPMENT 195
18.11 GABA THERAPEUTICS, INC. 196
18.11.1 COMPANY SNAPSHOT 196
18.11.2 PIPELINE PRODUCT PORTFOLIO 196
18.11.3 RECENT DEVELOPMENT 196
18.12 HIKMA PHARMACEUTICALS PLC 197
18.12.1 COMPANY SNAPSHOT 197
18.12.2 REVENUE ANALYSIS 197
18.12.3 PRODUCT PORTFOLIO 198
18.12.4 RECENT DEVELOPMENTS 198
18.13 MIND MEDICINE INC. 199
18.13.1 COMPANY SNAPSHOT 199
18.13.2 PIPELINE PRODUCT PORTFOLIO 199
18.13.3 RECENT DEVELOPMENTS 199
18.14 NEURORX, INC. 200
18.14.1 COMPANY SNAPSHOT 200
18.14.2 PIPELINE PRODUCT PORTFOLIO 200
18.14.3 RECENT DEVELOPMENTS 201
18.15 PHARMATHER HOLDINGS LTD. 202
18.15.1 COMPANY SNAPSHOT 202
18.15.2 PIPELINE PRODUCT PORTFOLIO 202
18.15.3 RECENT DEVELOPMENTS 203
18.16 USONAINSTITUTE.ORG 204
18.16.1 INSTITUTE SNAPSHOT 204
18.16.2 PIPELINE PRODUCT PORTFOLIO 204
18.16.3 RECENT DEVELOPMENTS 204
18.17 VERRIAN 205
18.17.1 COMPANY SNAPSHOT 205
18.17.2 PRODUCT PORTFOLIO 205
18.17.3 RECENT DEVELOPMENT 205
19 QUESTIONNAIRE 206
20 RELATED REPORTS 210